{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-035661","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.001164+00:00","generated_at":"2026-05-15T08:40:04.153275+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BioXcel posts Q4 net loss $12.5M, IGALMI revenue falls; sNDA filed for at-home use","bullets":["Q4 2025 IGALMI revenue $256K vs $366K in Q4 2024; full year $642K vs $2.3M.","Net loss Q4 $12.5M ($10.9M Q4 2024); full year $69.9M ($59.6M 2024).","Cash $28.8M at Dec 31, 2025; operating cash use $57.6M in 2025 vs $72M in 2024.","sNDA submitted Jan 2026 for IGALMI in at-home agitation; potential approval year-end 2026.","Appointed Mark Pavao as Interim CCO to lead launch plans for IGALMI at-home."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-035661","json":"https://secwatch.observer/filing/0001104659-26-035661.json","markdown":"https://secwatch.observer/filing/0001104659-26-035661.md","text":"https://secwatch.observer/filing/0001104659-26-035661.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926035661/0001104659-26-035661-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926035661/tm269970d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:40:04.153275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5e084d3d8985e7beacc50be8546e260f4dbf94e8","claim":"BioXcel Therapeutics, Inc. reported financial results for for the three months and year ended December 31, 2025.","evidence_excerpt":"On March 27, 2026, BioXcel Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months and year ended December 31, 2025 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926035661/0001104659-26-035661-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the three months and year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}